Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1945 1
1946 1
1956 2
1957 1
1958 1
1965 4
1966 6
1967 11
1968 10
1969 10
1970 25
1971 24
1972 23
1973 26
1974 45
1975 31
1976 31
1977 22
1978 31
1979 18
1980 21
1981 37
1982 37
1983 44
1984 47
1985 43
1986 47
1987 29
1988 36
1989 47
1990 45
1991 64
1992 66
1993 78
1994 83
1995 63
1996 76
1997 100
1998 92
1999 115
2000 119
2001 126
2002 108
2003 165
2004 128
2005 115
2006 148
2007 156
2008 152
2009 175
2010 164
2011 172
2012 183
2013 214
2014 185
2015 210
2016 213
2017 208
2018 229
2019 217
2020 204
2021 170
2022 179
2023 168
2024 68

Text availability

Article attribute

Article type

Publication date

Search Results

5,184 results

Results by year

Filters applied: . Clear all
Page 1
Review of Mavacamten for Obstructive Hypertrophic Cardiomyopathy and Future Directions.
Dong T, Alencherry B, Ospina S, Desai MY. Dong T, et al. Drug Des Devel Ther. 2023 Apr 8;17:1097-1106. doi: 10.2147/DDDT.S368590. eCollection 2023. Drug Des Devel Ther. 2023. PMID: 37064432 Free PMC article. Review.
Patients can experience exertional symptoms such as chest pain, dyspnea and syncope. Traditional treatment has included beta blockers and nondihydropyridine calcium channel blockers with second-line therapy being disopyramide. ...This review focuses on the pharmacology of …
Patients can experience exertional symptoms such as chest pain, dyspnea and syncope. Traditional treatment has included beta blockers …
Hypertrophic cardiomyopathy.
Santos Mateo JJ, Sabater Molina M, Gimeno Blanes JR. Santos Mateo JJ, et al. Med Clin (Barc). 2018 Jun 8;150(11):434-442. doi: 10.1016/j.medcli.2017.09.013. Epub 2017 Nov 14. Med Clin (Barc). 2018. PMID: 29150126 Review. English, Spanish.
It is characterized by increased ventricular wall thickness and is highly complex due to its heterogeneous clinical presentation, several phenotypes, large number of associated causal mutations and broad spectrum of complications. It is caused by mutations in sarcomeric pr …
It is characterized by increased ventricular wall thickness and is highly complex due to its heterogeneous clinical presentation, sev …
Cardioneuroablation for vasovagal syncope: A systematic review and meta-analysis.
Vandenberk B, Lei LY, Ballantyne B, Vickers D, Liang Z, Sheldon RS, Chew DS, Aksu T, Raj SR, Morillo CA. Vandenberk B, et al. Heart Rhythm. 2022 Nov;19(11):1804-1812. doi: 10.1016/j.hrthm.2022.06.017. Epub 2022 Jun 16. Heart Rhythm. 2022. PMID: 35716859
METHODS: A systematic search was performed in MEDLINE and EMBASE according to the PRISMA guidelines until February 14, 2022. Observational studies and clinical trials reporting freedom from syncope were included. Meta-analysis was performed with a random-effe …
METHODS: A systematic search was performed in MEDLINE and EMBASE according to the PRISMA guidelines until February 14, 2022. Observational s …
Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (RACE): a multicentre, phase 3, open-label, randomised controlled trial and ancillary follow-up study.
Jaïs X, Brenot P, Bouvaist H, Jevnikar M, Canuet M, Chabanne C, Chaouat A, Cottin V, De Groote P, Favrolt N, Horeau-Langlard D, Magro P, Savale L, Prévot G, Renard S, Sitbon O, Parent F, Trésorier R, Tromeur C, Piedvache C, Grimaldi L, Fadel E, Montani D, Humbert M, Simonneau G. Jaïs X, et al. Lancet Respir Med. 2022 Oct;10(10):961-971. doi: 10.1016/S2213-2600(22)00214-4. Epub 2022 Aug 1. Lancet Respir Med. 2022. PMID: 35926542 Clinical Trial.
Patients were randomly assigned (1:1) to BPA or riociguat via a web-based randomisation system, with block randomisation (block sizes of two or four patients) without stratification. ...This trial is registered at ClinicalTrials.gov, NCT02634203, and i …
Patients were randomly assigned (1:1) to BPA or riociguat via a web-based randomisation system, with block randomisation …
Cardioneuroablation for Reflex Syncope: Efficacy and Effects on Autonomic Cardiac Regulation-A Prospective Randomized Trial.
Piotrowski R, Baran J, Sikorska A, Krynski T, Kulakowski P. Piotrowski R, et al. JACC Clin Electrophysiol. 2023 Jan;9(1):85-95. doi: 10.1016/j.jacep.2022.08.011. Epub 2022 Aug 28. JACC Clin Electrophysiol. 2023. PMID: 36114133 Free article. Clinical Trial.
OBJECTIVES: This study sought to assess the effects of CNA on syncope recurrences in patients with VVS. METHODS: This study was a prospective, open, randomized, controlled, investigator-initiated trial comparing CNA versus optimal nonpharmacologic therapy in …
OBJECTIVES: This study sought to assess the effects of CNA on syncope recurrences in patients with VVS. METHODS: This study was a pro …
Pacemaker therapy in syncope.
Moya A, Roca-Luque I, Francisco-Pascual J, Perez-Rodón J, Rivas N. Moya A, et al. Cardiol Clin. 2013 Feb;31(1):131-42. doi: 10.1016/j.ccl.2012.10.001. Cardiol Clin. 2013. PMID: 23217694 Review.
The current evidence for pacemaker therapy is reviewed in 2 different syncopal conditions: reflex syncope with cardioinhibitory response and syncope in patients with bundle branch block. ...Ongoing clinical trials will answer this question....
The current evidence for pacemaker therapy is reviewed in 2 different syncopal conditions: reflex syncope with cardioinhibitory respo …
Association between antihypertensive treatment and adverse events: systematic review and meta-analysis.
Albasri A, Hattle M, Koshiaris C, Dunnigan A, Paxton B, Fox SE, Smith M, Archer L, Levis B, Payne RA, Riley RD, Roberts N, Snell KIE, Lay-Flurrie S, Usher-Smith J, Stevens R, Hobbs FDR, McManus RJ, Sheppard JP; STRATIFY investigators. Albasri A, et al. BMJ. 2021 Feb 10;372:n189. doi: 10.1136/bmj.n189. BMJ. 2021. PMID: 33568342 Free PMC article.
INFORMATION SOURCES: Searches were conducted in Embase, Medline, CENTRAL, and the Science Citation Index databases from inception until 14 April 2020. MAIN OUTCOME MEASURES: The primary outcome was falls during trial follow-up. Secondary outcomes were acute kidney injury, …
INFORMATION SOURCES: Searches were conducted in Embase, Medline, CENTRAL, and the Science Citation Index databases from inception until 14 A …
Carotid sinus syndrome.
Seifer C. Seifer C. Cardiol Clin. 2013 Feb;31(1):111-21. doi: 10.1016/j.ccl.2012.10.002. Cardiol Clin. 2013. PMID: 23217692 Review.
Nevertheless, a complete understanding of this relatively common clinical finding in older patients has proven elusive. There is evidence to support an association between symptoms, particularly syncope, and a hypersensitive response to carotid sinus massage. ...Alt …
Nevertheless, a complete understanding of this relatively common clinical finding in older patients has proven elusive. There is evid …
Bosentan.
Prakash A, Perry CM. Prakash A, et al. Am J Cardiovasc Drugs. 2002;2(5):335-43; discussion 343. doi: 10.2165/00129784-200202050-00006. Am J Cardiovasc Drugs. 2002. PMID: 14727963 Review.
Bosentan significantly reduced the incidence, and delayed the onset, of clinical worsening of pulmonary arterial hypertension compared with placebo. In published clinical trials, adverse events that occurred with similar or greater frequency with bosentan 125 mg twi …
Bosentan significantly reduced the incidence, and delayed the onset, of clinical worsening of pulmonary arterial hypertension compare …
Brexanolone for postpartum depression.
Hutcherson TC, Cieri-Hutcherson NE, Gosciak MF. Hutcherson TC, et al. Am J Health Syst Pharm. 2020 Feb 19;77(5):336-345. doi: 10.1093/ajhp/zxz333. Am J Health Syst Pharm. 2020. PMID: 32073124 Review.
The most frequent adverse events in brexanolone-treated patients were sedation, dizziness, somnolence, and headache. The severe or serious adverse effect of presyncope, syncope, or loss of consciousness was reported by 4% of participants. ...Significant concerns remain reg …
The most frequent adverse events in brexanolone-treated patients were sedation, dizziness, somnolence, and headache. The severe or serious a …
5,184 results